Tango Therapeutics raises $566.5M in public offering, extending cash runway into 2030

Filed June 10, 2026 · Period ending June 9, 2026 · ~1 min read

Key Changes

• high

  Tango sold 18.2 million shares at $30.00 each plus 1.8 million pre-funded warrants at $29.999, raising approximately $566.5 million after fees through J.P. Morgan and Leerink Partners.

  Item 1.01 verify on EDGAR →
• high

  Proceeds will fund R&D, pivotal trial expenses, commercialization preparation, and operations. Combined with existing cash, this extends the company's runway into 2030.

  Item 1.01 verify on EDGAR →
• medium

  Pre-funded warrants have a nominal $0.001 exercise price and are immediately exercisable with no expiration, but include ownership caps at 4.99% or 9.99% to prevent concentrated dilution.

  Item 1.01 verify on EDGAR →